teclistamab,talquetamab,daratumumab
janssen,genmab
['bet', 'mmsm', 'monumental-1', 'daratumumab', ' eve ', 'teclistamab', 'talquetamab']
monumental-1 phase 1/2 results: key takeaways. quick response (73-74%) in this difficult patient population (r/r-median of 6 prior lines of therapy). allows more flexibility with dose reductions, treatment vacations due to ae's. #imfash22 #ash22 #myeloma #mmsm 
Oncology nurse since 2006; Myeloma Advocate & SG Leader; Blessed Mom of 3; Doubly blessed Bonus Mom of 4; Honored to be Nonna of 2; Newfy Mom